Technical Analysis for BBI - Brickell Biotech, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical BBI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | -4.55% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Outside Day | about 23 hours ago |
| Down 3% | about 23 hours ago |
| Down 2 % | about 23 hours ago |
| Fell Below Previous Day's Low | about 23 hours ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/09/2021
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead products candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. The company was founded in 2009 and is based in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Organ Systems Lymphoma Psoriasis Stage Pharmaceutical Skin Diseases Cutaneous T Cell Lymphoma Hyperhidrosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Organ Systems Lymphoma Psoriasis Stage Pharmaceutical Skin Diseases Cutaneous T Cell Lymphoma Hyperhidrosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.61 |
| 52 Week Low | 0.466 |
| Average Volume | 2,780,197 |
| 200-Day Moving Average | 0.93 |
| 50-Day Moving Average | 1.22 |
| 20-Day Moving Average | 1.10 |
| 10-Day Moving Average | 1.02 |
| Average True Range | 0.09 |
| ADX | 16.09 |
| +DI | 15.02 |
| -DI | 32.09 |
| Chandelier Exit (Long, 3 ATRs ) | 1.12 |
| Chandelier Exit (Short, 3 ATRs ) | 1.11 |
| Upper Bollinger Band | 1.35 |
| Lower Bollinger Band | 0.86 |
| Percent B (%b) | -0.05 |
| BandWidth | 43.80 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.0281 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.95 | ||||
| Resistance 3 (R3) | 0.96 | 0.93 | 0.93 | ||
| Resistance 2 (R2) | 0.93 | 0.91 | 0.93 | 0.92 | |
| Resistance 1 (R1) | 0.89 | 0.89 | 0.88 | 0.88 | 0.92 |
| Pivot Point | 0.86 | 0.86 | 0.86 | 0.86 | 0.86 |
| Support 1 (S1) | 0.82 | 0.84 | 0.81 | 0.81 | 0.76 |
| Support 2 (S2) | 0.79 | 0.82 | 0.79 | 0.76 | |
| Support 3 (S3) | 0.75 | 0.79 | 0.75 | ||
| Support 4 (S4) | 0.74 |
